trending Market Intelligence /marketintelligence/en/news-insights/trending/fm3kyucbp-s2-hptttbxew2 content esgSubNav
In This List

Fibrocell closes stock offering, warrants placement

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Fibrocell closes stock offering, warrants placement

Fibrocell Science Inc. closed a previously announced direct offering of common stock, as well as a private placement of unregistered warrants.

Under the offering, the Exton, Pa.-based biotechnology company sold 2,038,224 common shares at $2.85 each, for gross proceeds of about $5.8 million.

Under the placement, Fibrocell issued warrants to buy 1,528,668 common shares, at 12.5 cents per warrant, for gross proceeds of about $200,000. The warrants' exercise price is $2.86 per share and are valid for 5.5 years from date of issue.

Net proceeds will go toward the clinical and preclinical development of the company's product candidates, FCX-007 and FCX-013, and for other general corporate purposes.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.